Baxter Recalls One Cefazolin IV Bag Lot Over Cardboard Particles

The FDA posted Baxter’s voluntary nationwide recall of one lot of Cefazolin in Dextrose Injection after cardboard particulate was found in the solution. The notice was published July 24, 2026, and applies only to lot LD175708—not to every Baxter cefazolin bag or every cefazolin product.

Baxter said it had received no reports of related adverse events when the notice was issued. The recall notice nevertheless states that foreign particles infused into a vein could cause pulmonary emboli, blockage of other blood vessels, phlebitis, immune-system activation, organ dysfunction or hemolysis.

Which bags are affected

Facilities should check inventory for Cefazolin in Dextrose Injection, USP, 2 grams in 100 milliliters, or 20 milligrams per milliliter. The affected product is a single-dose infusion bag in a 100 mL GALAXY plastic container and is identified as a frozen premix.

• Product code: 2G3508
• Lot: LD175708
• Expiration date: February 14, 2027
• NDC: 0338-3508-41

The recalled bags were distributed nationwide in the United States from March 25, 2025, through June 30, 2025. Those distribution dates are separate from the FDA’s July 24, 2026, publication of the recall.

What facilities should do

Baxter and the FDA-posted notice say customers should immediately stop using affected units. Hospitals, pharmacies and other facilities should check their stock, isolate any bags from lot LD175708 and arrange returns through their established Baxter or distributor process.

Facilities should use the lot number, expiration date and NDC—not the drug name alone—to determine whether a bag is covered. The recall is voluntary and limited to the identified lot.

What patients should know

Patients who received an infusion should not stop or change medication on their own. Questions about a particular treatment or product should be directed to the treating hospital, pharmacy or clinician, who can check product records and determine whether the recalled lot was involved.

People who believe they experienced a serious reaction, or who want to report a product-quality concern, can use the FDA’s MedWatch reporting program. Useful details include the manufacturer, drug strength, NDC, lot number, treatment date and description of the problem. Anyone experiencing severe or emergency symptoms should seek immediate medical care.

What to watch next

The next important updates would be any FDA or Baxter information about the investigation, the recall’s status, replacement supply or newly reported adverse events. The July 24 notice did not establish the source or manufacturing cause of the cardboard particulate.

Sources

• FDA MedWatch reporting guidance